Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc.（CAPR）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CAPR · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
7
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Capricor Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CAPR 季度内部人买卖趋势
CAPR 内幕交易卖出 · CAPR 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CAPR CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CAPR 高管卖出股份 · CAPR 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option | 3,000 | $4K | Form 4 |
| May 13, 2026 | Litvack Frank Director | Option | 3,937 | $5K | Form 4 |
| May 1, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option | 25,000 | $80K | Form 4 |
| May 1, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale | 25,000 | $793K | Form 4 |
| May 1, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option | 25,000 | $80K | Form 4 |
| May 1, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale | 25,000 | $793K | Form 4 |
| Apr 2, 2026 | Sabar Karimah Es Director | Option | 7,529 | $24K | Form 4 |
| Apr 2, 2026 | Sabar Karimah Es Director | Sale | 7,529 | $241K | Form 4 |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option | 2,819 | $9K | Form 4 |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option | 21,488 | $80K | Form 4 |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Option | 693 | $963 | Form 4 |
| Mar 31, 2026 | Krasney Karen EVP, GENERAL COUNSEL | Sale | 25,000 | $753K | Form 4 |
| Mar 31, 2026 | Sabar Karimah Es Director | Option | 61,265 | $298K | Form 4 |
| Apr 1, 2026 | Sabar Karimah Es Director | Option | 53,735 | $261K | Form 4 |
| Mar 31, 2026 | Sabar Karimah Es Director | Sale | 61,265 | $1.85M⚡ | Form 4 |
| Apr 1, 2026 | Sabar Karimah Es Director | Sale | 53,735 | $1.67M⚡ | Form 4 |
| Mar 31, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option | 25,000 | $80K | Form 4 |
| Mar 31, 2026 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Sale | 25,000 | $753K | Form 4 |
| Dec 30, 2025 | Krasney Karen EVP, GENERAL COUNSEL | Option | 2,500 | $3K | Form 4 |
| Dec 19, 2025 | DUNBAR GEORGE W JR Director | Option | 3,000 | $4K | Form 4 |
| Mar 3, 2025 | Marban Linda CHIEF EXECUTIVE OFFICER · Director | Option | 25,000 | $35K | Form 4 |
| Mar 5, 2025 | Marban Linda CHIEF EXECUTIVE OFFICER · Director | Other | 12,500 | — | Form 4 |
| Mar 3, 2025 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Option | 2,500 | $3K | Form 4 |
| Mar 3, 2025 | Litvack Frank Director | Option | 25,000 | $35K | Form 4 |
| Mar 3, 2025 | Litvack Frank Director | Other | 2,543 | $35K | Form 4 |
Marban Linda
CHIEF EXECUTIVE OFFICER · Director
日期
Mar 3
股数
25,000
均价
$1.39
总金额
$35K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CAPR 内幕交易
CAPR 内幕交易
Capricor Therapeutics, Inc.（CAPR）内幕交易数据来源于公司内部人（包括Krasney Karen (EVP, GENERAL COUNSEL), Sabar Karimah Es (Director), Bergmann Anthony (CHIEF FINANCIAL OFFICER)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CAPR内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Capricor Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CAPR 内幕交易 · 5个问题Capricor Therapeutics, Inc.（CAPR）的内部人包括高管和董事，如Krasney Karen (EVP, GENERAL COUNSEL), Sabar Karimah Es (Director), Bergmann Anthony (CHIEF FINANCIAL OFFICER)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026